For millions of people worldwide living with osteoarthritis, daily life is frequently characterized by a frustrating and often debilitating cycle of chronic pain, morning stiffness, and progressive joint dysfunction. While modern medicine offers a variety of therapeutic interventions—ranging from over-the-counter anti-inflammatory medications and physical therapy to systemic painkillers and corticosteroid injections—these conventional approaches share a fundamental limitation. They are designed primarily to temporarily dull the ache or manage flare-ups, but they ultimately fail to halt, slow down, or reverse the underlying structural deterioration of the joint.
Now, a groundbreaking preclinical study conducted by researchers at Yale University and published in the peer-reviewed journal Bioactive Materials points toward a profoundly different therapeutic strategy. The research team discovered that lacosamide, an FDA-approved medication traditionally prescribed to manage epilepsy, can serve as a highly effective, dual-purpose treatment capable of simultaneously relieving joint pain and reversing structural cartilage damage. Crucially, this regenerative and analgesic effect is dramatically enhanced when the medication is administered directly into the affected joint via a specialized, high-tech smart hydrogel.
The findings represent a significant conceptual shift in how scientists understand and approach osteoarthritis. By combining an existing pharmaceutical agent with advanced biomaterials, the Yale research team has opened a promising pathway toward true disease-modification, offering hope that future patients may avoid the invasive joint reconstruction surgeries, such as total knee replacements, that so often loom as the final outcome of the condition.
Understanding Osteoarthritis and the Limits of Current Care
Osteoarthritis is frequently described in everyday language as a simple "wear-and-tear" condition associated with aging or physical overuse. However, biomedical researchers emphasize that this common phrase drastically oversimplifies a remarkably complex biological and cellular process that scientists are still working to fully map and master.
Inside a healthy joint, specialized cells known as chondrocytes maintain a delicate and vital equilibrium between two opposing metabolic tasks: synthesizing new cartilage matrix components and breaking down old, damaged tissue. When osteoarthritis develops, this finely tuned homeostatic balance is severely disrupted. Destructive biological and mechanical forces begin to dominate the microenvironment, causing the rate of cartilage loss to accelerate dramatically. Over time, as the protective cushioning wears away completely, bare bones begin to rub directly against one another, generating severe friction, chronic inflammation, and agonizing pain.
"There is a major unmet need in osteoarthritis," says the study’s principal investigator, Chuan-Ju Liu, PhD, who serves as the Charles W. Ohse Professor of Orthopaedics & Rehabilitation at Yale. "We need therapies that don’t just mask pain, but actually change how the disease progresses."
At present, there is no widely available U.S. Food and Drug Administration-approved therapeutic capable of simultaneously halting this structural degeneration while providing lasting pain relief without significant systemic toxicity or the heavy risks of addiction associated with long-term opioid use. However, Liu and his colleagues set out to explore an innovative hypothesis by investigating cellular targets that govern both pain perception and tissue preservation.
A New Target Inside Cartilage Cells
The core of Liu’s research centers on a specific protein called Nav1.7, which functions as a voltage-gated sodium channel. In basic cellular biology, sodium channels operate much like microscopic electrical gates on cell membranes, facilitating the transmission of electrical signals across cellular networks.
For decades, the prevailing scientific consensus assumed that Nav1.7 was located almost exclusively within specialized peripheral nerve cells—the sensory pathways responsible for transmitting pain signals from the limbs up to the central nervous system. Because of this distribution, pharmaceutical companies had previously targeted Nav1.7 primarily for the development of novel pain medications.
However, Liu’s recent investigations uncovered a surprising and pivotal biological fact: this exact same sodium channel is also expressed and highly active inside chondrocytes, the structural cells residing deep within joint cartilage.
In a healthy joint, Nav1.7 remains relatively quiescent. But in an anatomical environment ravaged by osteoarthritis, the channel becomes aberrantly overactive. This pathological overactivity acts much like a volume knob turned up too high. It not only amplifies pain signaling to the nervous system, but it also triggers chondrocytes to switch into a destructive phenotype, causing them to actively break down the vital cartilage matrix they are biologically programmed to protect and maintain.
This unexpected discovery fundamentally alters how researchers view the pathology of osteoarthritis, elevating Nav1.7 into a rare and valuable dual-purpose therapeutic target capable of simultaneously influencing both neural pain perception and local tissue integrity.
"When Nav1.7 becomes dysregulated, it contributes to both joint degeneration and pain," Liu notes. "Our findings suggest that Nav1.7 is a dual-acting target. By blocking this single protein, we can potentially quiet the pain nerves and tell the cartilage cells to not only stop breaking down, but start repairing as well."
Repurposing an Epilepsy Drug for Joint Repair
Rather than spending decades designing, synthesizing, and testing an entirely new chemical entity from scratch, Liu’s research team evaluated existing classes of sodium channel inhibitors to see if any current pharmaceuticals could be safely repurposed to target Nav1.7 within the joint.
Their screening pointed toward lacosamide, an established medication long utilized in clinical neurology to control epileptic seizures. In rigorous laboratory and preclinical experiments, lacosamide demonstrated powerful biological activity against the targeted pathway at much lower concentrations than older, traditional sodium channel blockers, while also exhibiting a significantly safer overall pharmacological profile.
During their experiments, the researchers observed a fascinating pharmacological phenomenon: lacosamide dosing did not follow the traditional linear rule where higher doses yield greater effects. Instead, at an ideal, highly specific low concentration, the drug performed optimally, encouraging chondrocytes to synthesize cartilage-building proteins while completely shutting down tissue-degrading enzymes. Conversely, if the dosage drifted even slightly too high or too low, the therapeutic benefit diminished.
"This tells us the system is finely tuned," Liu explains. "There is an optimal range where the drug helps restore balance without overcorrecting. What stood out was not just its effectiveness, but how little of a dose was needed."
To understand the downstream mechanisms driving this protection, the Yale team analyzed how lacosamide influences cellular communication within the joint. They discovered that the drug triggers the localized release of two protective signaling proteins: heat shock protein 70 (HSP70) and midkine. These endogenous molecules act effectively as internal bodyguards for the joint environment. HSP70 assists cells in recovering from metabolic and mechanical stress while actively promoting tissue repair, whereas midkine helps regulate inflammation and shields joint tissues from ongoing degeneration.
"These proteins create a supportive environment for cartilage maintenance," Liu says. "They allow the effects of the drug to extend beyond individual cells and influence the entire tissue."
High-Tech Gel Delivery Extends Relief
While systemic or oral delivery of lacosamide showed efficacy in early laboratory assessments, administering the drug via traditional pills or injections poses significant pharmacokinetic challenges. Oral medications must circulate throughout the entire human body via the bloodstream, raising the risk of systemic side effects and diluting the concentration of the drug by the time it reaches the avascular cartilage environment.
To bypass these systemic drawbacks, researchers prefer intra-articular injection—delivering therapeutics directly into the joint cavity via a targeted needle. Yet, the knee joint, which is the most frequent anatomical site for osteoarthritis development, presents a formidable physiological barrier.
"The knee joint naturally acts like a leaky bucket," Liu describes. "The body’s natural lymphatic and vascular drainage systems can clear out standard liquids injected into the knee within hours."
To solve this dilemma, Liu’s team collaborated to develop a specialized, advanced hydrogel engineered from Collagen II, a primary structural protein found naturally in cartilage. This innovative material is thermoresponsive, meaning it maintains a liquid state inside a cool medical syringe for easy administration, but rapidly transitions into a sturdy, cohesive, jelly-like matrix upon encountering the internal warmth of the human body.
Once in place, this smart hydrogel functions as a localized pharmacological reservoir. It traps the precise, optimal concentration of lacosamide directly inside the joint microenvironment and meters it out through a slow, sustained release process lasting for weeks.
In preclinical trials, a single intra-articular injection of the lacosamide-loaded hydrogel administered once every four weeks proved remarkably superior at preventing progressive cartilage loss compared to daily oral administration of the drug.
A Faster Path to Clinical Use
Because lacosamide is already an established, FDA-approved pharmaceutical with a well-documented human safety record, the regulatory and translational pathway toward human clinical trials in osteoarthritis patients could be substantially accelerated compared to the development of entirely novel molecular compounds. Furthermore, human clinical data already exists demonstrating lacosamide’s safety and efficacy in treating specific nerve-related pain disorders linked to genetic Nav1.7 mutations, granting researchers heightened confidence that these preclinical laboratory findings will successfully translate into meaningful, real-world relief for patients.
This Yale study also exemplifies a broader, highly promising evolution in modern biomedical research: the convergence of targeted pharmacology with advanced biomaterial science to revolutionize drug delivery systems. For millions of individuals suffering from degenerative joint diseases, this interdisciplinary approach could ultimately translate into fewer invasive medical interventions, reduced systemic side effects, and long-lasting structural protection for vulnerable joints.
"We are not just developing a treatment," Liu concludes. "We are developing a system that allows the medicine to work more effectively where it matters most. Our goal is to move beyond symptom control and towards true disease modification. This effort brings us closer to that reality."
